IN2014DN03061A - - Google Patents

Info

Publication number
IN2014DN03061A
IN2014DN03061A IN3061DEN2014A IN2014DN03061A IN 2014DN03061 A IN2014DN03061 A IN 2014DN03061A IN 3061DEN2014 A IN3061DEN2014 A IN 3061DEN2014A IN 2014DN03061 A IN2014DN03061 A IN 2014DN03061A
Authority
IN
India
Prior art keywords
protein
acid sequences
adenoviral
adenovirus
pertaining
Prior art date
Application number
Other languages
English (en)
Inventor
Duncan McVEY
Douglas E Brough
Jason G D Gall
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of IN2014DN03061A publication Critical patent/IN2014DN03061A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN3061DEN2014 2011-10-05 2012-10-05 IN2014DN03061A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543652P 2011-10-05 2011-10-05
PCT/US2012/058978 WO2013052811A2 (en) 2011-10-05 2012-10-05 Adenoviral vectors and methods of use

Publications (1)

Publication Number Publication Date
IN2014DN03061A true IN2014DN03061A (cg-RX-API-DMAC7.html) 2015-05-15

Family

ID=47045180

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3061DEN2014 IN2014DN03061A (cg-RX-API-DMAC7.html) 2011-10-05 2012-10-05

Country Status (9)

Country Link
US (3) US9629906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2764013B1 (cg-RX-API-DMAC7.html)
JP (2) JP6757120B2 (cg-RX-API-DMAC7.html)
CN (2) CN107937440A (cg-RX-API-DMAC7.html)
BR (1) BR112014008249B1 (cg-RX-API-DMAC7.html)
CA (1) CA2850627C (cg-RX-API-DMAC7.html)
HK (1) HK1252010A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03061A (cg-RX-API-DMAC7.html)
WO (1) WO2013052811A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764014B1 (en) 2011-10-05 2022-02-09 GenVec, Inc. Adenoviral vectors and methods of use
CN107937440A (zh) * 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
IN2014DN03005A (cg-RX-API-DMAC7.html) 2011-10-05 2015-05-08 Genvec Inc
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
US9676824B2 (en) * 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
JP7118062B2 (ja) 2016-12-09 2022-08-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リサウイルス抗原を有するチンパンジーアデノウイルス構築物
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
EP3775175A4 (en) 2018-04-09 2022-02-09 Salk Institute for Biological Studies ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH IMPROVED REPLICATION PROPERTIES
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CZ287157B6 (en) 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP0885012A4 (en) 1996-01-29 2001-09-05 Univ Georgetown MALARIA Vaccine, which also contains an MSA1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
CA2348158A1 (fr) * 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
PL209133B1 (pl) * 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
ATE449105T1 (de) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
CA2590943C (en) 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
RU2604815C2 (ru) 2009-02-02 2016-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нуклеинокислотные и аминокислотные последовательности аденовируса обезьян, векторы, содержащие указанные последовательности, и их применение
EP2459716B1 (en) 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
JP5980117B2 (ja) * 2009-11-09 2016-08-31 ジェンヴェック，インコーポレーテッド サルアデノウイルスベクターの増殖方法
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP2764014B1 (en) 2011-10-05 2022-02-09 GenVec, Inc. Adenoviral vectors and methods of use
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
IN2014DN03005A (cg-RX-API-DMAC7.html) * 2011-10-05 2015-05-08 Genvec Inc
CN107937440A (zh) * 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
EP2809346A1 (en) 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine

Also Published As

Publication number Publication date
CN107937440A (zh) 2018-04-20
CA2850627A1 (en) 2013-04-11
US10272162B2 (en) 2019-04-30
BR112014008249A2 (pt) 2017-04-18
WO2013052811A3 (en) 2013-06-20
US20170246318A1 (en) 2017-08-31
CA2850627C (en) 2024-05-21
JP2014530605A (ja) 2014-11-20
US9629906B2 (en) 2017-04-25
JP2018198603A (ja) 2018-12-20
JP6970060B2 (ja) 2021-11-24
HK1252010A1 (zh) 2019-05-10
BR112014008249B1 (pt) 2022-03-15
US20140248308A1 (en) 2014-09-04
CN103974970B (zh) 2018-01-02
WO2013052811A2 (en) 2013-04-11
EP2764013B1 (en) 2022-01-26
EP2764013A2 (en) 2014-08-13
JP6757120B2 (ja) 2020-09-16
CN103974970A (zh) 2014-08-06
US20190269794A1 (en) 2019-09-05
US10792376B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
IN2014DN03061A (cg-RX-API-DMAC7.html)
IN2014DN03005A (cg-RX-API-DMAC7.html)
WO2013052832A3 (en) Simian (gorilla) adenovirus or adenoviral vectors and methods of use
IL219882A0 (en) System for increasing gene expression and vector comprising the system
WO2015168547A3 (en) In vivo gene engineering with adenoviral vectors
SG11201403450VA (en) Artificial nucleic acid molecules for improved protein or peptide expression
PH12012500908A1 (en) Methods of propagating monkey adenoviral vectors
AU2011356210A8 (en) Novel fucosyltransferases and their applications
EP2582397A4 (en) COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
ZA201309016B (en) Simian adenovirus and hybrid adenoviral vectors
WO2012027572A3 (en) Methods for nucleic acid capture and sequencing
IL228328B (en) Aav vectors without capsid, preparations and methods for vector preparation and gene transfer
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
EP2726559A4 (en) FUNGAL EXTRACTION COATINGS ON POLYSILOXAN BASE WITH ENZYMES
IT1395511B1 (it) Apparato per riscaldamento con microonde di prodotti planari
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
EP2592944A4 (en) BEVERAGES WITH HIGH PROTEIN CONTENT AND WHEY PROTEINS
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
PL3461888T3 (pl) Ulegające zużyciu krioprezerwowane komórki wykazujące przejściową nadekspresję genu(-ów) kodującego(-ych) białko(-a) transportera leku i/lub enzym(y) metabolizujący(-e) lek
WO2017041063A3 (en) Compositions and methods for identifying genetic predisposition to obesity and for enhancing adipogenesis
PL2681532T3 (pl) Wyznaczanie DNA i/lub RNA na podstawie danych ze spektrofotometru UV-VIS
SG2014009187A (en) Dna element having the activity of enhancing foreign gene expression
GB201004143D0 (en) Promoter sequence for DNA and viral vectors